Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug ZT002 tested for safety with other medications

NCT ID NCT07550816

Recruiting now Knowledge-focused Sponsor: Beijing QL Biopharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study looks at how ZT002, a long-acting experimental drug for weight management, affects the way the body processes four common medications (metformin, warfarin, rosuvastatin, and digoxin). About 60 overweight or obese but otherwise healthy adults aged 18-45 will take these drugs with and without ZT002 to measure any changes. The goal is purely to gather safety and interaction data, not to treat or cure obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT , OBESITY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Second Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.